Skip to content
Catalyst

resveratrolFinding

Resveratrol has no detected effect on aspartate aminotransferase

no difference foundLimited evidenceFinding

01 · The sentence it was drawn from

“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.
This finding among the 57 findings on its endpoint

resveratrol

Aspartate aminotransferase

no difference found

Effect as reported

−0.39standardised mean difference

CI −0.95 to 0.16

Who
adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Dose studied
300-3,000 mg/day, 8-24 weeks, pooled across trials

Limited evidencePMID 37767399 · 2023

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limitedthis finding
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3RM66AEDYQ0Y6RZN0H7ZBSD